Abstract
In the last few years, substantial progress has been achieved in elucidating the pathogenesis of Wegener’s granulomatosis. Several genetic risk factors have been described. The structure of the granuloma and its possible function as ectopic lymphoid tissue have been defined. Furthermore, the consecutive immunopathological reactions leading to induction of PR3-antineutrophil cytoplasmic antibodies (ANCA) and the role of ANCA itself is getting clearer. However, the initial events leading to granuloma formation are still widely unknown. Concerning therapy, the significance of the so-called biological agents (TNF-α-blockers, Rituximab) still has to be defined.
Similar content being viewed by others
References
Jagiello P, Gencik M, Arning L, Wieczorek S, Kunstmann E, Csernok E, Gross WL, Epplen JT (2004) Hum Genet 114:469–477
Heckmann M, Holle JU, Arning L, Knaup S, Hellmich B, Nothnagel M, Jagiello P, Gross WL, Epplen JT, Wieczorek S (2007) Ann Rheum Dis (in press)
Jagiello P, Aries P, Arning L, Wagenleiter SE, Csernok E, Hellmich B, Gross WL, Epplen JT (2005) Arthritis Rheum 52:4039–4043
Zhou Y, Huang D, Paris PL, Sauter CS, Prock KA, Hoffman GS (2004) Arthritis Rheum 50:2645–2650
Muraközy G, Gaede KI, Ruprecht B, Gutzeit O, Schürmann M, Schnabel A, Schlaak M, Gross WL, Müller-Quernheim J (2001) J Mol Med 79:665–670
Watts RA, Scott DGI, Fujimoto S et al (2007) Clin Exp Rheumatol 25:S–95
Komocsi A, Lamprecht P, Csernok E, Mueller A, Holl-Ulrich K, Seitzer U, Moosig F, Schnabel A, Gross WL (2002) Am J Pathol 160:1717–1724
Voswinkel J, Mueller A, Kraemer JA, Lamprecht P, Herlyn K, Holl-Ulrich K, Feller AC, Pitann S, Gause A, Gross WL (2006) Ann Rheum Dis 65:859–864
Csernok E, Ai M, Gross WL, Wicklein D, Petersen A, Lindner B, Lamprecht P, Holle JU, Hellmich B (2006) Blood 107:4440–4448
Csernok E, Ernst M, Schmitt W, Bainton DF, Gross WL (1994) Clin Exp Immunol 95:244–250
Gilligan HM, Bredy B, Brady HR, Hébert MJ, Slayter HS, Xu Y, Rauch J, Shia MA, Koh JS, Levine JS (1996) J Exp Med 184:2231–2241
Moosig F, Csernok E, Kumanovics G, Gross WL (2000) Clin Exp Immunol 122:499–503
Kantari C, Pederzoli-Ribeil M, Amir-Moazami O, Gausson-Dorey V, Moura IC, Lecomte MC, Benhamou M, Witko-Sarsat V (2007) Blood 110:4086–4095
von Vietinghoff S, Tunnemann G, Eulenberg C, Wellner M, Cristina Cardoso M, Luft FC, Kettritz R (2007) Blood 109:4487–4493
Finkielman JD, Lee AS, Hummel AM, Viss MA, Jacob GL, Homburger HA, Peikert T, Hoffman GS, Merkel PA, Spiera R, St Clair EW, Davis JC Jr, McCune WJ, Tibbs AK, Ytterberg SR, Stone JH, Specks U, WGET Research Group (2007) Am J Med 120:643
Hellmich B, Csernok E, Fredenhagen G, Gross WL (2007) Clin Exp Rheumatol 25:S1–S5
Rarok AA, Stegeman CA, Limburg PC, Kallenberg CG (2002) J Am Soc Nephrol 13:2232–2238
Wegener’s Granulomatosis Etanercept Trial (WGET) Research Group (2005) N Engl J Med 352:351–361
Hellmich B, Lamprecht P, Gross WL (2006) Curr Opin Rheumatol 18:25–32
Mukhtyar C, Luqmani R (2005) Ann Rheum Dis 64:vi31–vi36
Keogh K, Wylam M, Stone J, Specks U (2005) Arthritis Rheum 52:262–268
Moser K, Muehlinghaus G, Manz R, Mei H, Voigt C, Yoshida T, Dörner T, Hiepe F, Radbruch A (2006) Immunol Lett 103:83–85
Smith KG, Jones RB, Burns SM, Jayne DR (2006) Arthritis Rheum 54:2970–2982
Falk RJ, Hoffman GS (2007) Curr Opin Rheumatol 19:1–9
Lamprecht P, Gross WL (2007) Clin Exp Rheumatol 25:S49–S51
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Moosig, F., Lamprecht, P. & Gross, W.L. Wegener’s Granulomatosis: The Current View. Clinic Rev Allerg Immunol 35, 19–21 (2008). https://doi.org/10.1007/s12016-007-8067-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12016-007-8067-5